Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
61.31
+0.73 (1.21%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Royalty Pharma Employees
Royalty Pharma had 100 employees as of December 31, 2025. The number of employees increased by 1 or 1.01% compared to the previous year.
Employees
100
Change (1Y)
1
Growth (1Y)
1.01%
Revenue / Employee
$25,359,980
Profits / Employee
$8,119,940
Market Cap
35.25B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 100 | 1 | 1.01% |
| Dec 31, 2024 | 99 | 10 | 11.24% |
| Dec 31, 2023 | 89 | 14 | 18.67% |
| Dec 31, 2022 | 75 | 9 | 13.64% |
| Dec 31, 2021 | 66 | 15 | 29.41% |
| Dec 31, 2020 | 51 | 16 | 45.71% |
| Dec 31, 2019 | 35 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 3,119 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
RPRX News
- 6 days ago - Zealand Pharma enters $100M royalty purchase, sale pact with Royalty Pharma - TheFly
- 10 days ago - Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million - GlobeNewsWire
- 10 days ago - Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide - GlobeNewsWire
- 11 days ago - Royalty Pharma Slides: Corporate presentation - Filings
- 16 days ago - Royalty Pharma price target raised to $66 from $59 at Goldman Sachs - TheFly
- 16 days ago - Royalty Pharma price target raised to $65 from $64 at Morgan Stanley - TheFly
- 17 days ago - Royalty Pharma price target raised to $70 from $66 at Citi - TheFly
- 17 days ago - Royalty Pharma Earnings Call Transcript: Q2 2026 - Transcripts